Company news

vTv Therapeutics Inc. news in 2024

vTv Therapeutics Inc.'s news releases, calls and decks from 2024, newest first.

View company

Cantex Pharmaceuticals receives FDA Orphan Drug Designation for azeliragon for the treatment of brain metastasis from breast cancer

December 8, 2024

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

December 1, 2024

vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update

November 11, 2024

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

August 7, 2024

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

July 25, 2024

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

June 23, 2024

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

May 8, 2024

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

March 12, 2024

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

March 3, 2024

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

February 29, 2024

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

February 27, 2024

Decks in 2024